FrontPharma Achieves Milestone with First-Ever Approval and Consistency Evaluation for Its 200+ Million RMB Ointment Product

FrontPharma has once again made remarkable achievements on the path of innovative development. According to reliable information, the company's carefully developed Mometasone furoate cream has recently been successfully approved by the State Drug Administration, and is the first similar product to pass the consistency evaluation. This milestone not only highlights FrontPharma's outstanding strength in research and development, but also further strengthens its industry leading position in the field of plasters.

Let's take a closer look at this cream first. Mometasone furoate cream is a widely used topical drug to treat skin inflammation, allergies and other symptoms. With its excellent efficacy and safety, it is highly favored in clinical applications. On the basis of inheriting the advantages of traditional Mometasone furoate cream, this cream developed by FrontPharma further improves the quality and efficacy of the product through technological innovation and process optimization.

According to authoritative data, FrontPharma's Mometasone furoate cream sales in the national hospital market exceeded 200 million yuan in 2023, with a year-on-year growth rate of 20.32%. This impressive achievement is a testament to the strong competitiveness and wide acceptance of FrontPharma's products in the market.

FrontPharma is not the only company in the field of Mometasone furoate cream with production approvals. Previously, a total of eight domestic pharmaceutical companies have the production qualification of this product, but unfortunately, these companies have not yet been able to complete the consistency evaluation. FrontPharma, with its excellent research and development strength and production capacity, successfully became the first company to pass the conformity evaluation. This honor not only highlights FrontPharma's leading position in research and development, but also gives it more advantages and opportunities in the market competition.

It is worth mentioning that FrontPharma's research and development strength in the field of ointment is not achieved overnight. In recent years, the company has continuously increased investment in research and development, actively introduced advanced technology and equipment, and strengthened the construction and training of research and development teams. These efforts have enabled FrontPharma to achieve significant results in the field of plasters. Up to now, the company has a number of varieties through the consistency evaluation, including some high-profile star products. The successful launch of these products has not only brought a better medication experience to patients, but also won FrontPharma more reputation and praise in the market competition.

Looking ahead, FrontPharma will continue to adhere to the strategic direction of innovative development and continue to introduce more innovative products. The company will continue to improve product quality and efficacy through continuous research and development and innovation, and bring better, safer and more convenient medication experience to patients. At the same time, FrontPharma will also actively participate in market competition and continue to expand its market share and influence, laying a solid foundation for the company's long-term development.

To sum up, FrontPharma has once again made remarkable achievements on the path of innovative development. This achievement not only highlights the company's R&D strength and market competitiveness, but also lays a solid foundation for its future development. We look forward to FrontPharma achieving even more brilliant achievements in its future development!